TABLE 1.
Summary of the effects of ω3-PUFA dietary supplementation on cardiac morphology and function following TAC
| CO Sham | CO TAC | FO TAC | EPA TAC | DHA TAC | |
| RBC FA% | |||||
| n | — | 18 | 20 | 15 | 16 |
| EPA | — | 0.27 ± 0.05 | 1.54 ± 0.04b | 2.71 ± 0.13b | 0.46 ± 0.09 |
| DHA | — | 4.83 ± 0.59 | 8.47 ± 0.79b | 8.09 ± 0.76b | 9.73 ± 1.17b |
| Pathology | |||||
| n | 5 | 18 | 20 | 16 | 19 |
| HW (mg) | 107.1 ± 4.2 | 176.8 ± 8.7a | 187.2 ± 8.6 | 183.4 ± 9.8 | 177.0 ± 8.6 |
| BW (g) | 24 ± 1 | 25 ± 0 | 25 ± 0 | 25 ± 0 | 24 ± 0 |
| HW/BW (mg/g) | 4.5 ± 0.2 | 7.1 ± 0.41a | 7.5 ± 0.3 | 7.5 ± 0.5 | 7.3 ± 0.4 |
| Echocardiography | |||||
| n | 5 | 19 | 19 | 15 | 19 |
| HR | 528 ± 6 | 517 ± 8 | 526 ± 4 | 533 ± 7 | 522 ± 5 |
| EF | 69.8 ± 4.3 | 52.4 ± 4.0a | 50.0 ± 3.9 | 48.1 ± 4.3 | 52.1 ± 4.2 |
| E/E’ | 19.4 ± 1.1 | 31.4 ± 1.9a | 34.2 ± 2.7 | 29.7 ± 2.1 | 28.7 ± 2.1 |
| AoV | 1001 ± 153 | 4736 ± 223a | 5000 ± 221 | 4459 ± 165 | 4676 ± 155 |
| Histology | |||||
| n | 5 | 14 | 14 | 10 | 14 |
| Fibrosis (%) | 1.46 ± 0.25 | 3.66 ± 0.97a | 2.55 ± 0.65 | 1.44 ± 0.29 | 3.54 ± 0.86 |
RBC FA%, erythrocyte FA percent; HR, heart rate; AoV, peak aortic velocity; Fibrosis, percentage of positive picrosirius red stain of ventricular tissue.
a
P < 0.05 versus CO Sham (t-test).
b
P < 0.05 versus CO TAC (one-way ANOVA, Tukey post-test).